GlassScriptPhysician profile
Shikha Jain
NPI 1053585463
$67,502.40
in general payments reported to CMS, 2019-2025
24 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $2,100 · 2021: $8.22 · 2022: $50.89 · 2023: $21K · 2024: $23K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $27K · Travel and Lodging: $2,194 · Food and Beverage: $1,488 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,877.50 |
| Consulting Fee | $26,600.00 |
| Travel and Lodging | $2,193.74 |
| Food and Beverage | $1,487.79 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $17,092.50 | 2023 | |
| Pfizer INC. | $13,279.30 | 2024 | |
| Jazz Pharmaceuticals INC. | $12,945.71 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $7,971.10 | 2022-2025 | Fruzaqla |
| Abbvie INC. | $4,037.85 | 2024-2025 | |
| Seagen INC. | $3,277.93 | 2023 | Tukysa |
| Tempus Ai, INC | $3,133.71 | 2024-2025 | Xt Cdx |
| Beone Medicines USA, INC. | $2,829.26 | 2025 | Tevimbra |
| E.R. Squibb & Sons, L.L.C. | $2,100.00 | 2020 | |
| Aveo Pharmaceuticals, INC. | $238.18 | 2023 | Fotivda |
| Exelixis INC. | $174.00 | 2024 | Cabometyx |
| Beigene USA, INC. | $146.04 | 2025 | Tevimbra, Brukinsa |
| Ipsen Biopharmaceuticals, INC | $79.00 | 2025 | |
| Boston Scientific Corporation | $52.63 | 2019 | |
| Cook Medical LLC | $52.63 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $21.83 | 2023 | Bavencio |
| Merck Sharp & Dohme LLC | $20.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $19.08 | 2023 | |
| Deciphera Pharmaceuticals INC. | $18.01 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.64 | 2024 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shikha Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.